What are the main functions and suitable groups of venetoclax (venetoclax)?

Venetoclax (Chinese name: Venetoclax) is a targeted drug that is a BCL-2 inhibitor and is mainly used to treat certain types of hematomas. tumors, especially those related to chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The mechanism of action of venetoclax is to promote the death of tumor cells by inhibiting the function of BCL-2 protein. BCL-2 is an important intracellular protein that inhibits apoptosis. Its overexpression plays a role in promoting the survival of tumor cells in various cancers. By targeting BCL-2, venetoclax can effectively induce apoptosis in cancer cells, thereby slowing down the progression of the disease.

The main indications for venetoclax are chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In chronic lymphocytic leukemia, venetoclax is often used in combination with other chemotherapy drugs and has shown promising results, particularly in patients who have failed to respond to conventional treatments. For acute myeloid leukemia, venetoclax is often used in combination with chemotherapy or with other targeted drugs, especially in patients with specific genetic mutations. In addition, venetoclax has been approved to treat other blood disorders related to BCL-2, such as certain types of non-Hodgkin lymphoma (NHL).

In terms of applicable population, venetoclax is suitable for patients with a variety of hematological tumors, especially those who have failed to respond to traditional treatments or other targeted treatments. For patients with chronic lymphocytic leukemia, especially high-risk groups with 17p deletions or TP53 mutations, venetoclax has shown significant therapeutic effects. Venetoclax is also part of the treatment regimen for patients with acute myeloid leukemia, especially those with mutations in genes such as IDH1, IDH2, and FLT3. In general, venetoclax is suitable for some patients with refractory, relapsed or high-risk hematological tumors.

Although venetoclax has significant efficacy, not all patients with hematologic malignancies are candidates for the drug. Before using venetoclax, patients must undergo detailed genetic testing to confirm whether they meet the drug's indications. Venetoclax should be used with caution in patients with severe hepatic impairment, renal insufficiency, or a known history of allergy. In addition, side effects of venetoclax may include low blood cell counts, infection, bleeding, etc., so patients need to be closely monitored for these possible side effects during treatment. Ensure the safety and effectiveness of the treatment plan through full communication with doctors.

Reference materials:https://www.venclexta.com/